| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B6-507 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-091
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-103 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01R33-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-055
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B8-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B6-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 |
| filingDate |
1996-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2004-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2004-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-100403755-B1 |
| titleOfInvention |
Diagnostic imaging contrast agent with extended blood retention |
| abstract |
The present invention provides diagnostic contrast contrast agents that exhibit improved blood retention. The novel compounds of the present invention comprise a) an image-enhancing (or signal-generating) moiety (IEM); b) Plasma protein binding portion (PPBM); And c) a blood half-life extension (BHEM). The present invention also relates to pharmaceutical compositions containing such compounds and to methods of using the compounds and pharmaceutical compositions for prolonging the blood half-life and enhancing contrast of diagnostic imaging. The contrast agonist decreases the absorption rate in the kidney and the absorption rate in hepatocytes, and is not absorbed by the RE system. The agent may target the blood pool or any other biological component. Because the agent is less rapidly lost from the blood stream, lower doses can be used with greater safety benefits. This method applies to both large and small molecules. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100762359-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100762357-B1 |
| priorityDate |
1995-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |